# Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

> **NCT00782379** · PHASE2 · COMPLETED · sponsor: **Northside Hospital, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **DRUG:** mycophenolate mofetil
- **DRUG:** tacrolimus
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00782379
- **Lead sponsor:** Northside Hospital, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-04
- **Final completion:** 2012-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782379, "Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00782379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*